• Immune Pharmaceuticals Ltd., of Herzliya-Pituach, Israel, and EpiCept Corp., of Tarrytown, N.Y., said Immune is initiating a Phase II double-blind placebo-controlled study with its lead drug bertilimumab in patients with moderate-to-severe ulcerative colitis.
Read More
BOSTON – Research backed by the Armed Forces Institute of Regenerative Medicine (AFIRM) since its formation in April 2008 will within the next five years lead to a range of marketed products that, taken together, will vastly improve the treatment of severe facial injuries, reducing the amount of surgery required and providing superior structural, functional and aesthetic results.
Read More
LONDON – Biotechs registered with the SME (small- and medium-sized enterprise) Office of the European Medicines Agency (EMA) have seen consistent improvements in the success rate of applications for marketing approvals, according to a report analyzing activity in the seven years since the office was set up in 2005.
Read More
The lineaments of Ireland's new science strategy are evident in its latest round of research funding, comprising €200 million (US$261 million) of public money, which will fund seven university-industry research centers over the next six years. Industry partners will add another €100 million through a mix of cash and in-kind contributions.
Read More
4SC AG could earn up to €96 million (US$125 million) in option and milestone payments arising out of a preclinical drug development deal in inflammatory skin disease with Leo Pharma A/S, as well as double-digit royalties on eventual product sales.
Read More
LONDON – Start-up BioMoti Ltd. secured its first private financing in a seed round of £150,000 (US$227,000) to advance its Oncojan platform technology, a microparticle carrier system combining targeted delivery of chemotherapy drugs with their controlled release within tumor cells.
Read More
LONDON – Identification of a protein that orchestrates many of the changes that permit a normal cell to turn into a cancer cell will open up an entirely new field of cancer therapeutics, the researchers who made the discovery predicted.
Read More
Shares in Gentium SpA fell 20 percent last week on news that the lengthy approval process for defibrotide, a drug for the treatment and prevention of hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem cell transplant, had just become longer.
Read More
